<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408979</url>
  </required_header>
  <id_info>
    <org_study_id>MgSO4</org_study_id>
    <nct_id>NCT01408979</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia</brief_title>
  <acronym>MgSO4</acronym>
  <official_title>Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal
      duration of this treatment after delivery is still to be established. The hypothesis is that
      in stable patients a shorter course of treatment is possible without prejudice to the
      mother.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium sulfate (MgSO4) is certainly the ideal drug for prevention and control of
      eclamptic seizures. However, there is no consensus on the appropriate duration of
      prophylaxis with this anticonvulsant postpartum.The objective of the present study is to
      compare effectiveness of 12 hours of magnesium sulfate versus 24 hours (standard treatment)
      in stable patients with preeclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Need to continue therapy for another 12 hours.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as the need to continue therapy for another 12 hours, this will occur when after the first 12 hours of magnesium sulfate therapy the patient has severe hypertension, unsatisfactory diureses or has signs or symptoms of iminent eclampsia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients satisfaction with the duration of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Severe Preeclampsia</condition>
  <arm_group>
    <arm_group_label>12 hours of magnesium sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have magnesium sulfate administered for 12 hours after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hours of magnesium sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will have magnesium sulfate administered for 24 hours after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate 12 hours</intervention_name>
    <description>Magnesium sulfate, 1g/h, (10% solution), for 12 hours</description>
    <arm_group_label>12 hours of magnesium sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate 24 hours</intervention_name>
    <description>Magnesium sulfate, 1g/h, (10% solution), for 24 hours</description>
    <arm_group_label>24 hours of magnesium sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-eclampsia;

          -  Puerperium.

        Exclusion Criteria:

          -  Associated maternal diseases;

          -  Use of illicit drugs or other medications that might interfere with maternal
             hemodynamics;

          -  Contraindications to the use of magnesium sulfate: drug hypersensitivity, oliguria
             with urine output below 25ml/h; anuria (absent urine output), myasthenia gravis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melania M Amorim, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIP</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50.000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>August 20, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Materno Infantil Prof. Fernando Figueira</investigator_affiliation>
    <investigator_full_name>Leila Katz</investigator_full_name>
    <investigator_title>Obstetrical ICU obstetrical coordinator; MD , PhD</investigator_title>
  </responsible_party>
  <keyword>Severe preeclampsia</keyword>
  <keyword>magnesium sulfate</keyword>
  <keyword>anticonvulsivant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
